Q1 Earnings Estimate for PHIO Issued By Sidoti Csr

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Equities researchers at Sidoti Csr issued their Q1 2027 EPS estimates for Phio Pharmaceuticals in a note issued to investors on Monday, November 17th. Sidoti Csr analyst A. Hantman expects that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ Q2 2027 earnings at ($0.19) EPS and Q3 2027 earnings at ($0.20) EPS.

Several other brokerages have also recently commented on PHIO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Phio Pharmaceuticals in a research note on Friday, August 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Trading Down 4.8%

PHIO stock opened at $1.19 on Wednesday. Phio Pharmaceuticals has a 12-month low of $0.97 and a 12-month high of $9.79. The business’s 50-day moving average is $2.00 and its 200 day moving average is $2.14. The stock has a market cap of $6.82 million, a price-to-earnings ratio of -0.37 and a beta of 0.97.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its earnings results on Thursday, November 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,694 shares of the company’s stock after purchasing an additional 16,108 shares during the quarter. Geode Capital Management LLC owned about 1.20% of Phio Pharmaceuticals worth $136,000 as of its most recent filing with the Securities and Exchange Commission. 57.31% of the stock is owned by hedge funds and other institutional investors.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.